Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval is backed by data showing deep, durable responses and manageable tolerability
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
Subscribe To Our Newsletter & Stay Updated